hackint0sh/New-Dataset huggingface dataset:
Upon enrollment, patients will be randomized 1:1 to receive either the experimental drug (Colchicine) or matching placebo. The regimen in the active arm will consist of 14 days of Colchicine 0.6 mg bid followed by 76±14 days of Colchicine 0.6 mg once per day. Placebo regimen will be analogous, with one pill bid for 14 days followed by one pill once per day for 76 days. Dose reduction for patients with Stage III chronic kidney disease is allowed as detailed in the protocol. At the same time, dose reduction can also be elected in case of GI symptoms. The study team will transiently stop the experimental medication in case of acute kidney injury (AKI), defined per Kidney Disease Improving Global Outcomes (KDIGO) Stage I, as specified in the protocol.
These patients will continue with their standard of care for the management of heart failure which consists of a combination of medications that relieve congestion, normalize blood pressure and heart rate, and block the effects of hormones on the heart. The proposed treatment will be in addition to standard of care. No standard of care medications will be withheld. While inflammation is a known risk factor in heart failure, there are no standard anti-inflammatory drugs used in patients with heart failure, as the benefit is not established. The study team will study colchicine, an anti-inflammatory drug, as compares with placebo.
Blood will be obtained from the patients in order to measure hsCRP and IL-6. Blood samples will be collected at baseline, 24±6h, 48±6h and 72±6h after treatment initiation, and subsequently at 14±7 days and at study closure. The first four blood samples will be obtained while the subject is still admitted to the hospital. The blood sample at 14±7 days will be obtained during an outpatient encounter. A study closure visit with clinical assessment and experimental drug collection for capsule counting to assess compliance will be conducted at 90±14; the final blood sample will be collected at that time. conditions: Heart Failure conditions: Decompensated Heart Failure conditions: Heart Failure With Reduced Ejection Fraction studyType: INTERVENTIONAL phases: PHASE4 allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: The study team is planning to use controls in the present study. Controls will be patients from the target population, i.e. acutely decompensated heart failure with reduced ejection fraction. primaryPurpose: TREATMENT masking: TRIPLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR count: 30 type: ESTIMATED name: Colchicine 0.6 mg name: Control/Placebo group measure: Difference in the change in high sensitivity C-reactive protein (hsCRP) between colchicine arm and placebo arm in the first 72 hours of treatment measure: Difference in hsCRP area under curve between colchicine and placebo arm at 14 days measure: Difference in change in plasma IL-6 concentration between colchicine arm and placebo arm in the first 72 hours of treatment measure: Difference in the incidence of a composite of all-cause mortality or hospitalizations for heart failure at 90 days sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: UVA Health status: RECRUITING city: Charlottesville state: Virginia zip: 22908 country: United States name: Austin Hogwood role: CONTACT email: ach2jb@virginia.edu name: Francesco Moroni, MD role: CONTACT email: nmf7mm@uvahealth.org name: Antonio Abbate, MD role: PRINCIPAL_INVESTIGATOR lat: 38.02931 lon: -78.47668 hasResults: False
nctId: NCT06286410 id: 184950 briefTitle: Accommodation Response in Hypermetropic Anisometropia (ARIHA Study) acronym: ARIHA overallStatus: NOT_YET_RECRUITING date: 2024-02 date: 2024-12 date: 2024-12 date: 2024-02-29 date: 2024-03-01 name: University of Sheffield class: OTHER name: Sheffield Children's NHS Foundation Trust briefSummary: Anisometropic amblyopia is when one eye has a much stronger glasses prescription than the other, causing poor vision in one eye, even with glasses, because the brain favours the better-seeing eye.
The investigators aim to use the non-invasive PR3 to assess accommodation in hypermetropic anisometropic amblyopia, at the University of Sheffield. This will be a two-phase study of children aged 4-10 years who have hypermetropic anisometropia. The investigators will recruit participants attending the Ophthalmology Department at Sheffield Children's NHS Foundation Trust (SCH). The investigators will take repeated measurements of accommodation at points during standard care treatment (phase 1) and conduct a pilot intervention study (phase 2) to determine whether adjusting glasses prescriptions based on accommodation responses with amblyopia treatment can improve vision in the weaker eye. The goal is to gather evidence to inform a future larger multicentre RCT to improve the visual outcomes for anisometropic amblyopic children in the future. conditions: Anisometropic Amblyopia conditions: Accommodation Disorder studyType: INTERVENTIONAL phases: NA allocation: NON_RANDOMIZED interventionModel: PARALLEL interventionModelDescription: During Phase 2 of the study:
Asymmetrical accommodation can be one of two things: Aniso-A and Anti-A. primaryPurpose: TREATMENT masking: NONE count: 22 type: ESTIMATED name: Bespoke glasses prescription worn during amblyopia treatment. measure: Change in visual acuity measure: Change in PR3 accommodation measurements sex: ALL minimumAge: 4 Years maximumAge: 10 Years stdAges: CHILD facility: Division of Ophthalmology & Orthoptics, School of Allied Health Professions, Nursing and Midwifery, The University of Sheffield city: Sheffield state: South Yorkshire zip: S10 2RX country: United Kingdom name: Holly Geraghty role: CONTACT phone: 0114 215 9005 email: hgeraghty@sheffield.ac.uk name: Gemma Arblaster role: CONTACT phone: 0114 215 9005 email: g.arblaster@sheffield.ac.uk name: Holly Geraghty role: PRINCIPAL_INVESTIGATOR lat: 53.38297 lon: -1.4659 hasResults: False
nctId: NCT06286397 id: 855173 briefTitle: Topical Anti-Androgens in Pilonidal Sinus Disease overallStatus: NOT_YET_RECRUITING date: 2024-05-01 date: 2027-05-01 date: 2027-12-01 date: 2024-02-29 date: 2024-03-04 name: University of Pennsylvania class: OTHER briefSummary: The goal of this randomized clinical trial is to test the topical drug clascoterone in patients with pilonidal disease, which is a common, benign skin condition of the gluteal cleft. The main questions it aims to answer are:
Researchers will compare participants who received clascoterone treatment to those who received placebo. conditions: Pilonidal Disease conditions: Pilonidal Disease of Natal Cleft conditions: Pilonidal Sinus conditions: Pilonidal Cyst studyType: INTERVENTIONAL phases: PHASE2 allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Randomized, Double-Blinded, Placebo-Controlled Trial primaryPurpose: TREATMENT masking: QUADRUPLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 75 type: ESTIMATED name: 1% Clascoterone name: Vehicle Cream measure: Physician-Assessed Disease Severity Assessment measure: Dermatology Life Quality Index measure: Subcutaneous Inflammation sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: University of Pennsylvania city: Philadelphia state: Pennsylvania zip: 19103 country: United States name: Lillias Maguire, MD role: CONTACT phone: 215-662-2078 email: lillias.maguire@pennmedicine.upenn.edu name: Lillias Maguire, MD role: PRINCIPAL_INVESTIGATOR lat: 39.95233 lon: -75.16379 hasResults: False
nctId: NCT06286384 id: LEMU47 briefTitle: Evaluating the Long-term Effects of Microfocused Ultrasound on Facial Tightening Using Quantitative Instruments overallStatus: RECRUITING date: 2023-07-03 date: 2024-09-15 date: 2025-03-15 date: 2024-02-29 date: 2024-02-29 name: First Affiliated Hospital of Jinan University class: OTHER briefSummary: By utilizing standardized photographs in conjunction with quantification detection instruments, data analysis before and after treatment is conducted, along with long-term efficacy observations. This approach aims to provide more comprehensive scientific evidence for the clinical application of ultrasound treatment in anti-aging therapy. conditions: Facial Aging studyType: OBSERVATIONAL observationalModel: OTHER timePerspective: PROSPECTIVE count: 32 type: ESTIMATED measure: Total Volume Change of Nasolabial Folds measure: Change in Maximum Depth of Nasolabial Folds measure: Vertical Elevation Value of Nasolabial Fold Curve Projection Curve measure: Elevation Value of Nasolabial Fold Curve Projection Curve (Along the Nasal Wing Method measure: Change in Mid-Facial Volume measure: Brow Lift Height sex: FEMALE minimumAge: 25 Years maximumAge: 60 Years stdAges: ADULT facility: First Affiliated Hospital of Jinan University status: RECRUITING city: Guangzhou state: Guangdong zip: 510000 country: China name: Xuangu LI role: CONTACT phone: +8613825136477 email: 443747565@qq.com lat: 23.11667 lon: 113.25 hasResults: False
nctId: NCT06286371 id: 2023-13/37 briefTitle: Pelvic Neuro-Angiogenesis in Deep Endometriosis overallStatus: RECRUITING date: 2023-12-01 date: 2024-09 date: 2025-04 date: 2024-02-29 date: 2024-03-04 name: Uludag University class: OTHER briefSummary: Endometriosis is observed in one out of every ten women in society, causing endometrial cells to be found outside their normal location in the body and proliferate in other locations, leading to fibrosis in the tissue due to the secretion of various factors from the cells. Additionally, the substances secreted by the cells can cause various other changes in the tissue besides fibrosis. Increased neurogenesis and neovascularization are among the primary changes, which occur as a result of the secretion of substances from the cells. Increased neovascularization, neurogenesis, and fibrosis in the tissue lead to the formation of nodular structures in the pelvic region, resulting in pain development in women.
In this project, in patients operated on due to endometriosis, the density of nerve and vascular structures in the surgical margins of the peritoneal tissue excised along with the nodule, and the synthesis and release of chemical mediators causing pain (e.g., Bradykinin, Substance-P) are evaluated. The aim is to determine the minimum surgical margin where excision should be applied in surgery and to demonstrate any endometriotic changes that may exist in the tissues, even though they may appear macroscopically healthy. conditions: Endometriosis-related Pain conditions: Endometriosis conditions: Deep Endometriosis conditions: Endometriosis; Peritoneum studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 15 type: ESTIMATED name: Laparoscopic Endometriosis Surgery measure: Density of Neuro-Angiogenesis measure: Density of Pain Mediators in Pelvic Peritoneum measure: Relationship between Neuro-Angiogenesis Density and Pelvic Pain Scores sex: FEMALE minimumAge: 18 Years maximumAge: 45 Years stdAges: ADULT facility: Uludag University Faculty Hospital status: RECRUITING city: Bursa state: Gorukle zip: 16285 country: Turkey name: Kiper Aslan, Assoc. Prof. role: CONTACT phone: +905548127272 email: kiperaslan@uludag.edu.tr name: Erberk Cimer, M.D. role: CONTACT phone: +905316770596 name: Kiper Aslan, Assoc. Prof. role: PRINCIPAL_INVESTIGATOR name: Erberk Cimer, M.D. role: PRINCIPAL_INVESTIGATOR name: Isil Kasapoglu, Assoc. Prof. role: SUB_INVESTIGATOR name: Cihan Cakir, M.D. role: SUB_INVESTIGATOR name: Berrin Avci, Prof. role: SUB_INVESTIGATOR name: Gurkan Uncu, Prof. role: SUB_INVESTIGATOR lat: 40.19559 lon: 29.06013 hasResults: False
nctId: NCT06286358 id: P2023/346 / CCB : B40620230001 briefTitle: Aortopathy Relationship To Imagery and Kinocardiography Features (ARTIK) acronym: ARTIK overallStatus: RECRUITING date: 2024-03-07 date: 2025-03-30 date: 2025-09-30 date: 2024-02-29 date: 2024-03-12 name: Université Libre de Bruxelles class: OTHER name: Erasme University Hospital briefSummary: Kinocardiography (KCG) is a portable measurement technique developed to estimate cardiac mechanical performance by studying the vibrations produced by myocardial contraction during each heartbeat and transmitted to the body surface.
In patients with AVD of different severities or TAA, the investigators will collect informations from echocardiography and/or cardiac magnetic resonance imaging and KCG recordings. Researchers will also compare subjects without any AVD nor TAA to better understand these effects on KCG. conditions: Aortic Valve Disease conditions: Aortic Aneurysm studyType: OBSERVATIONAL observationalModel: CASE_CONTROL timePerspective: PROSPECTIVE count: 180 type: ESTIMATED name: Kinocardiography measure: Understand and assess the complex mechanisms underlying the modifications of KCG signals in patients with AVD and/or TAA measure: Comparing KCG to clinical assessment measure: Asses the clinical application of KCG to diagnose AVD and TAA sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Erasme hospital status: RECRUITING city: Brussels zip: 1070 country: Belgium name: Philippe van de Borne, MD, PhD role: CONTACT phone: 2 555 39 60 phoneExt: +32 email: philippe.vandeborne@hubruxelles.be name: Philippe van de Borne, MD, PhD role: PRINCIPAL_INVESTIGATOR name: Elza Abdessater, MD role: SUB_INVESTIGATOR lat: 50.85045 lon: 4.34878 hasResults: False
nctId: NCT06286332 id: Interventional briefTitle: Music Therapy in Acute Leukemia Patients With Fatigue overallStatus: NOT_YET_RECRUITING date: 2024-03-01 date: 2026-03-01 date: 2026-03-01 date: 2024-02-29 date: 2024-03-06 name: Chang Gung University class: OTHER briefSummary: The objective of this study is to assess the efficacy of employing music therapy in alleviating fatigue and medical laboratory values among patients with acute myeloid leukemia. conditions: Acute Myeloid Leukemia conditions: Fatigue studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: SUPPORTIVE_CARE masking: DOUBLE whoMasked: CARE_PROVIDER whoMasked: OUTCOMES_ASSESSOR count: 60 type: ESTIMATED name: Music Therapy measure: Change from baseline in fatigue on the Tang Fatigue Rating Scale (TFRS) and 11-point Numeric Rating Scale (NRS-11) at day 21. measure: Change from baseline in neutrophil, hemoglobin, abumin at day 21. sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06286319 id: 23-00726 briefTitle: Cold Oxygen Lung Preservation and Ventilation With the "Angel Cooler" overallStatus: NOT_YET_RECRUITING date: 2024-04 date: 2026-04 date: 2026-04 date: 2024-02-29 date: 2024-02-29 name: NYU Langone Health class: OTHER briefSummary: The objective of this feasibility study is to evaluate continuous temperature monitoring, oxygen (O2) concentration and ventilation with positive end expiratory pressure (PEEP) to keep lungs cooled at 4-8 degrees Celsius, with continuous O2 concentration of 100% and inflated with a PEEP of 8-10 during the entire cold ischemic period. conditions: Lung Diseases studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: DEVICE_FEASIBILITY masking: NONE count: 20 type: ESTIMATED name: Angel Cooler measure: Proportion of Devices Deemed "Functional" sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: NYU Langone Health city: New York state: New York zip: 10016 country: United States lat: 40.71427 lon: -74.00597 hasResults: False
nctId: NCT06286306 id: 2022_0232 id: 2022-A02813-40 type: OTHER domain: ID-RCB number, ANSM briefTitle: Pronostic Value of Fluid Responsiveness Evaluated by Inferior Vena Cava Collapsibility Index in Patients Admitted in ICU With Acute Respiratory Failure acronym: PRIVACY overallStatus: RECRUITING date: 2023-02-24 date: 2025-05-25 date: 2025-05-25 date: 2024-02-29 date: 2024-02-29 name: University Hospital, Lille class: OTHER briefSummary: Acute respiratory failure represents a frequent cause of admission to intensive care units (ICUs). In the absence of tailored interventions, it poses an imminent threat to patients' lives. Most patients admitted in ICU undergo fluid expansion to enhance oxygen delivery and preserve cellular function.
Upon receipt of both oral and written information, patients will provide non-objection to participate in the study. This prospective single-center study has obtained approval from the Regional Ethics Committee of Ile de France III approval (No. 2022-A02813-40). conditions: Hypoxemic Without Hypercapnia Acute Respiratory Failure studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 50 type: ESTIMATED measure: Association between fluid responsiveness and death or the need of invasive mechanical ventilation measure: All cause mortality measure: Need of invasive mechanical ventilation measure: Days alive without vasopressor agents measure: Days alive without mechanical ventilation or oxygen support measure: Days alive without renal replacement therapy measure: Days alive without vasopressor agents, mechanical ventilation, oxygen support, and renal replacement therapy sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Hopital Roger Salengro status: RECRUITING city: Lille zip: 59037 country: France name: PREAU Sebastien, Md PHd role: CONTACT phone: 03 20 44 64 45 email: sebastien.preau@chu-lille.fr name: Delforge Quentin, Md role: CONTACT phone: 0320446445 email: quentin.delforge@chu-lille.fr lat: 50.63297 lon: 3.05858 hasResults: False
nctId: NCT06286293 id: 18171 briefTitle: YOD-RiSoCo: Social Cognition and Risky Decision-making in Patients With Young-onset Dementia acronym: YOD-RiSoCo overallStatus: NOT_YET_RECRUITING date: 2024-06-01 date: 2026-06-30 date: 2027-03-31 date: 2024-02-29 date: 2024-03-04 name: University Medical Center Groningen class: OTHER name: ZonMw: The Netherlands Organisation for Health Research and Development briefSummary: The goal of this observational study is to learn about social cognition and risky behaviour in patients with young-onset dementia (YOD). The investigators want to
Participants will be administered a neuropsychological assessment including social cognition measures and patients will complete a driving simulator task in which risky behaviour will be elicited. conditions: Young-onset Dementia studyType: OBSERVATIONAL observationalModel: CASE_CONTROL timePerspective: CROSS_SECTIONAL count: 140 type: ESTIMATED name: Neuropsychological assessment, driving simulator task measure: Social cognitive performance measure: Association between social cognition and risky decision-making sex: ALL minimumAge: 18 Years maximumAge: 70 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06286280 id: AZ221/21 id: F/23/22 type: OTHER_GRANT domain: German Foundation of Heart Research briefTitle: Removal Of CytoKines With cytoSorbenTs After Inflammatory Response Reaction During Cardiac Surgery acronym: ROCKSTAR overallStatus: RECRUITING date: 2023-05-01 date: 2024-12-01 date: 2025-05-01 date: 2024-02-29 date: 2024-03-18 name: University of Giessen class: OTHER name: Deutsche Stiftung für Herzforschung briefSummary: Detailed knowledge about the association between systemic inflammation and endothelial progenitor cell (EPCs) activation during extracorporeal circulation (ECC) is lacking.
This pilot study aims to clarify the relationship between CD34-positive EPCs and cytokine release during ECC using the cytokine adsorber to make a predictive statement regarding the clinical expression of inflammation. conditions: Inflammatory Response studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: single-center, two-arm randomized-controlled prospective study primaryPurpose: BASIC_SCIENCE masking: SINGLE maskingDescription: Participant will not be informed about group allocation whoMasked: PARTICIPANT count: 50 type: ESTIMATED name: cytokine adsorber (CytoSorb®) measure: correlation of endothelial progenitor cells with cytokine levels with and without adsorber use measure: Overall mortality rate measure: Days on ventilator, vasopressor and renal replacement therapy measure: incidence of stroke measure: length of ICU and in-hospital stay measure: Echocardiographic changes measure: Influence of Cytokine on endothelial progenitor cells sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Universityhospital Giessen, Department of Cardiovascular Surgery status: RECRUITING city: Giessen zip: 35392 country: Germany name: Zulfugar T Taghiyev, MD, MBA role: CONTACT phone: 80064198556743 email: gk5019@uni-giessen.de name: Zulfugar T Taghiyev, MD, MBA role: PRINCIPAL_INVESTIGATOR lat: 50.58727 lon: 8.67554 hasResults: False
nctId: NCT06286267 id: SYSKY-2023-351-02 briefTitle: AI-Assisted System for Accurate Diagnosis and Prognosis of Breast Phyllodes Tumors overallStatus: RECRUITING date: 2023-03-01 date: 2027-12-31 date: 2027-12-31 date: 2024-02-29 date: 2024-02-29 name: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University class: OTHER name: Sun Yat-sen University name: Peking University Shenzhen Hospital name: Guangdong Provincial Maternal and Child Health Hospital name: The Third Affiliated Hospital of Guangzhou Medical University briefSummary: Breast phyllodes tumor (PT) is a rare fibroepithelial tumor, accounting for 1% to 3% of all breast tumors, categorized by the WHO into benign, borderline, and malignant, based on histopathology features such as tumor border, stromal cellularity, stromal atypia, mitotic activity and stromal overgrowth. Malignant PTs account for 18%-25%, with high local recurrence (up to 65%) and distant metastasis rates (16%-25%). Benign PT could progress to malignancy after multiple recurrences. Therefore, Early, accurate diagnosis and identification of therapeutic targets are crucial for improving outcomes and survival rates.
In recent years, there has been growing interest in the application of artificial intelligence (AI) in medical diagnostics. AI can integrate clinical information, histopathological images, and multi-omics data to assist in pathological and clinical diagnosis, prognosis prediction, and molecular profiling.AI has shown promising results in various areas, including the diagnosis of different cancers such as colorectal cancer, breast cancer, and prostate cancer. However, PT differs from breast cancer in diagnosis and treatment approach. Therefore, establishing an AI-based system for the precise diagnosis and prognosis assessment of PT is crucial for personalized medicine.
The research team, led by Dr. Nie Yan, is one of the few in Guangdong Province and even nationally, specializing in PT research. Their team has been conducting research on the malignant progression, metastasis mechanisms, and molecular markers for PT. The team has identified key mechanisms, such as fibroblast-to-myofibroblast differentiation, and the role of tumor-associated macrophages in promoting this differentiation. They have also identified molecular markers, including miR-21, α-SMA, CCL18, and CCL5, which are more accurate in predicting tumor recurrence risk compared to traditional histopathological grading.